Applications of N-Desmethylclozapine in Industrial Manufacturing

As a manufacturer of N-Desmethylclozapine, we supply this pharmaceutical intermediate for advanced downstream processes in regulated industries. Below are several key sectors utilizing our material, with a focus on specification-driven integration, strict compliance, and end-use applications.

1. Atypical Antipsychotic API Synthesis

N-Desmethylclozapine serves as a core intermediate in the synthesis of atypical antipsychotic active pharmaceutical ingredients, particularly within the olanzapine and clozapine API manufacturing sectors. Downstream pharmaceutical producers depend on this compound for precise conversion steps, namely via methylation or demethylation reactions that deliver high-purity end products ready for tableting or encapsulation. Our product integrates directly after the initial aromatic ring formation, meeting narrow impurity profiles. Consistent assay and chemical integrity streamline production batch records for solid oral drug forms. End formulations require tight impurity control and specification traceability from intermediate to API conversion.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• European Pharmacopoeia, monographs for APIs
• US FDA 21 CFR Part 211, cGMP for Finished Pharmaceuticals
• Chinese Pharmacopoeia requirements for raw materials and intermediates

Typical usage ratio

• Employed at 1.00–1.10 molar equivalents relative to final API target, slight excess to drive reaction to completion; finalized based on API yield and residual impurity levels

Downstream process integration

• Fed directly into condensation and functional group conversion stage following initial benzodiazepine scaffold assembly
• Purified via crystallization prior to next methylation or derivatization step

Final product types

• Olanzapine tablets
• Clozapine tablets and oral suspensions
• Pharmaceutical bulk APIs for antipsychotic drug manufacturing

2. Reference Standards for Analytical Method Development

Many pharmaceutical quality control laboratories use N-Desmethylclozapine as a certified reference standard during method validation and impurity profiling for antipsychotic drug substances and finished formulations. It serves as a key marker compound for forced degradation studies, HPLC, UPLC, and LC-MS development, especially in stability testing protocols. Laboratories require traceability, batch consistency, and impurity data at each use, which are supported by our validated Certificate of Analysis and manufacturing traceability. Careful weighing, dilution, and calibration procedures ensure that method performance meets both regulatory and client demands.

Industry compliance standards

• United States Pharmacopeia (USP) <795> and <797> for analytical standards handling
• WHO Good Practices for Pharmaceutical Quality Control Laboratories
• ISO/IEC 17025 for chemical testing laboratories
• FDA guidelines on analytical method validation (ICH Q2(R2))

Typical usage ratio

• Prepared as 0.1–10 µg/mL standard solutions; concentration depends on analytical technique and sensitivity requirements

Downstream process integration

• Dissolved in acetonitrile or methanol for calibration curve preparation
• Spiked into placebo or finished dosage samples to determine recovery rates and precision

Final product types

• Analytical standards kits for pharmaceutical QC labs
• Pharmaceutical method validation documentation packages
• Pharmacopoeial impurity reference standards

3. Research Compound for CNS Drug Discovery

Academic and industrial research teams utilize this molecule for in vitro and in vivo central nervous system (CNS) receptor binding assays and pharmacological profiling. It enables mechanistic studies into dopamine and serotonin receptor activity, supporting lead compound optimization in preclinical CNS pipelines. Researchers frequently require certified purity, specific isotopic labeling, or bespoke packaging, which we accommodate through lot-based quality documentation. Usage protocols vary according to research goals, with common applications including cell culture exposure, ex vivo brain tissue binding studies, and animal model pharmacokinetic profiling.

Industry compliance standards

• GLP (Good Laboratory Practice) OECD Principles
• IACUC or equivalent national animal research oversight
• NIH Guidelines for Research Involving Chemical Hazards

Typical usage ratio

• Dosed in vitro at 0.01–10 µM; in animal models, administered at 0.1–10 mg/kg body weight depending on study design and ethical approvals

Downstream process integration

• Reconstituted in DMSO or saline at required dose levels
• Added during ligand competition or receptor functional assays
• Delivered via oral or intraperitoneal dosing in preclinical animal studies

Final product types

• Small molecule library compounds for CNS screening
• Custom-labeled research reagents
• Data packets for scientific publication or intellectual property filings

4. Metabolite Marker for Clinical Bioanalytical Testing

Clinical laboratories and contract research organizations deploy this compound as a metabolite marker in therapeutic drug monitoring and bioanalytical quantification of antipsychotic metabolism. Its role includes serving as an external or internal standard in LC-MS/MS assays for patient plasma or urine samples, correlating N-Desmethylclozapine levels with drug adherence or metabolic profile. Our manufacturing specification supports ultra-high purity, low endotoxin load, and lot-to-lot reproducibility validated under accredited quality systems, which meet the rigorous demands of clinical assay validation and regulatory submission.

Industry compliance standards

• Clinical Laboratory Improvement Amendments (CLIA) for US clinical labs
• CAP Laboratory Accreditation Standards
• EMA Guideline on Bioanalytical Method Validation
• FDA Guidance for Industry – Bioanalytical Method Validation (May 2018)

Typical usage ratio

• Applied as internal standard at 1–100 ng/mL dependent on assay detection limit and sample volume; adjusted for calibration curve linearity

Downstream process integration

• Diluted with control plasma or buffer as part of calibration and QC sample sets
• Included during sample extraction, protein precipitation, or solid-phase extraction workflows

Final product types

• Validated clinical test kits for drug metabolism studies
• Certified LC-MS/MS method standards for pharmacokinetic evaluation
• Patient test result reports for therapeutic monitoring